ImQuest BioSciences Revenue and Competitors

Frederick, MD USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ImQuest BioSciences's estimated annual revenue is currently $2.6M per year.(i)
  • ImQuest BioSciences's estimated revenue per employee is $155,000

Employee Data

  • ImQuest BioSciences has 17 Employees.(i)
  • ImQuest BioSciences grew their employee count by 0% last year.

ImQuest BioSciences's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
Director, Anti-Infective ResearchReveal Email/Phone
3
Director, Topical Microbicide ResearchReveal Email/Phone
4
Director, Cell and Molecular Biology Research ServicesReveal Email/Phone
5
Research AssociateReveal Email/Phone
6
Research AssociateReveal Email/Phone
7
Research AssistantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is ImQuest BioSciences?

ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases. As part of our ImQuest SUCCESS platform, we provide expert preclinical research services, including compound screening to define compound efficacy and drug target validation analysis to define the mechanism of action and toxicity of pharmaceutical products. We specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines for infectious disease and cancer drug development programs. Our preclinical contract research services are comprised of interrelated efficacy-defining components for infectious disease (including microbiology and virology), cancer and women's health with parallel evaluations of in vitro and ex vivo toxicity and the pharmaceutical properties and chemical structure of preclinical candidates to efficiently validate you drug target. We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. Our team has decades of experience in the field of virology, microbiology and oncology. As such, we understand that each product and each client is unique and we strive to provide effective solutions.

keywords:N/A

N/A

Total Funding

17

Number of Employees

$2.6M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M176%N/A
#2
$1.6M17-41%N/A
#3
$1.5M17325%N/A
#4
$2.1M17-43%N/A
#5
$2.1M17N/AN/A